Dana Farber Cancer Institute SC

Boston, Massachusetts 02215

0 studies enrolling now · 5 studies all time

What they study most

Advanced NET of GI Origin, Advanced NET of Lung Origin, Brain Metastasis, Endometrial Cancer, Neuroendocrine Tumors, Non-small Cell Lung Cancer, Second-line Treatment, Solid Tumors, Solid Tumors and Advanced Endometrial Cancer, VEGF, c-MET Inhibitor; PI3K Inhibitor, PTEN Mutations, Homozygous Del. of PTEN or PTEN Neg. by IHC, c-Met Ampli. by FISH, INC280, BKM120, Buparlisib; Recurrent GBM

Studies at this site

• Everolimus Plus Best Supportive Care vs Placebo Plus Best Supportive Care in the Treatment of Patients With Advanced Neuroendocrine Tumors (GI or Lung Origin) — Completed
• Study of Patupilone in Patients With Brain Metastasis From Non-small Cell Lung Cancer — Completed
• A Study of LCL161 in Combination With Weekly Paclitaxel in Adult Patients With Advanced Solid Tumors — Completed
• Safety and Efficacy of INC280 and Buparlisib (BKM120) in Patients With Recurrent Glioblastoma — Stopped early
• A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer — Completed